A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis

Renal impairment (RI) is a major complication of multiple myeloma (MM). This study aimed to characterize the single‐dose pharmacokinetics (PK) of the oral proteasome inhibitor, ixazomib, in cancer patients with normal renal function [creatinine clearance (CrCl) ≥90 ml/min; n = 20), severe RI (CrCl &...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Hanley, Michael J., Harvey, R. Donald, Badros, Ashraf, Lipe, Brea, Kukreti, Vishal, Berdeja, Jesus, Yang, Huyuan, Hui, Ai‐Min, Qian, Mark, Zhang, Xiaoquan, Venkatakrishnan, Karthik, Chari, Ajai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084759/
https://www.ncbi.nlm.nih.gov/pubmed/27196567
http://dx.doi.org/10.1111/bjh.14125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084759/
https://www.ncbi.nlm.nih.gov/pubmed/27196567
http://dx.doi.org/10.1111/bjh.14125

Ejemplares similares